---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021638"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:40:04.577867+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lipocine misses Q1 EPS estimates; LPCN 1154 PPD Phase 3 fails primary endpoint

## Summary
- Net loss of $3.7M ($0.52/share) vs $1.9M loss ($0.35) in Q1 2025; cash $24.7M.
- Phase 3 trial of LPCN 1154 for postpartum depression missed primary endpoint; HAM-D reduction vs placebo not significant at hour 60.
- LPCN 1154 well-tolerated; no serious AEs, sedation, or loss of consciousness; post hoc significance in patients with psychiatric history (n=54).
- Company applied for breakthrough/fast track designations for LPCN 1154; evaluating validation study or strategic options.
- TLANDO royalty revenue $119K in Q1 2026 versus $94K in prior year.

## SEC filing metadata
- accession: 0001493152-26-021638
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/0001493152-26-021638-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021638
- JSON: https://secwatch.observer/filing/0001493152-26-021638.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021638.txt

## Source-grounded claims
- claim_id: 55ea8acd9fa31bc1c6648b15bc8253585e545cab
  claim: Lipocine Inc. reported First Quarter Ended March 31, 2026 results: net income net loss of $3.7 million, EPS ($0.52) per diluted share.
  evidence_excerpt: Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/0001493152-26-021638-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.